Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI in
patients with HER2-negative breast cancer, who have documented Central Nervous System (CNS)
progression following Whole Brain Radio Therapy (WBRT), Stereotactic Radiosurgery (SRS)
and/or surgery, as determined by the Response Assessment in Neuro-Oncology Brain Metastases
(RANO-BM) criteria.